Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Status:
Completed
Trial end date:
2017-11-13
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well everolimus works in treating patients with recurrent
low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth or by blocking blood flow to the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Susan Chang University of California, San Francisco